bioAffinity Technologies shares are trading higher after the company announced it received a notice of allowance for a U.S. patent titled "DETECTION OF EARLY-STAGE LUNG CANCER IN SPUTUM USING AUTOMATED FLOW CYTOMETRY AND MACHINE LEARNING"